Colorectal cancer and circulating concentrations of soluble lymphocyte activation molecules: Relations to disease activity and tumour burden

International Journal of Immunopathology and Pharmacology

Volumn 9, Issue 3, 1996, Pages 123-129

  Piancatelli, D ^a   Maccarone, D ^a   Del Beato, T ^a   Famulari, A ^b   Adorno, D ^a   Casciani, C U ^a  

^a CNR Ist Tipizzazione TPD   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Colorectal neoplasm; Cytokines; Lymphocyte subsets; Soluble interleukin 2 receptor

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; SOLUBLE INTERLEUKIN 2 RECEPTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BLOOD LEVEL; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; COLON ADENOMA; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0030460291     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Buer J., H. Kirchner, A. Schomburg, A. Schuler, M. Manns, E. Lopez-Hanninen, S. Duensing, H. Poliwoda and J. Atzpodien. 1994. Cytokine-based biotherapy of gastrointestinal tumors. J. Clin. Invest. 72:526.
2. J.P.J. Brakenhoff. 1995. Interleukin-6 receptor antagonists. Dig. Neurol. Psych. 8:397.
3. T. Hirano. 1992. Interleukin-6 and its relation to inflammation and disease. Clin. Immunol. Immunopathol. 62:S60.
4. Blay J.Y., S. Negrier, V. Combaret V., S. Attaii, E. Goillot E., Y. Merrouche, A. Mercatello, A. Ravault, J.M. Tourani, J.F. Moskovtchenko and T. Philip. 1992. Serum levels if interleukin-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res. 52:3317.
5. Scambia G., U. Testa, P. Benedetti Panici, R. Martucci, E. Foti, M. Petrini, M. Amoroso, V. Masciullo, C. Peschle and S. Mancuso. 1994. Interleukin-6 serum levels in patients with gynecological tumors. Int. J. Cancer 57:318.
6. Rubin L.A. and D.L. Nelson. 1990. The Soluble Interleukin-2 Receptor: Biology, Function and Clinical Application. Ann. of Intern. Med. 113: 619.
7. Whittington R. and D. Faulds. 1993. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46:446.
8. R.O. Dillman. 1994. The clinical experience with interleukin-2 in cancer therapy. Cancer Biother. 9:183.
9. Semenzato G., R. Foa, C. Agostini, R. Zambello, L. Trentin, F. Vinante, F. Benedetti, M. Chilosi and G. Pizzolo. 1987. High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood 70: 396.
10. Ambrosetti A., G. Nadali, F. Vinante, S. Carlini, D. Veneri, G. Todeschini, L. Morosato, D. de Sabata, M. Chilosi, E. Maggi, P. Parronchi, S. Romagnani, G. Semenzato, G. Perona and G. Pizzolo. 1993. Serum levels of soluble IL-2 receptor in Hodgkin disease. Cancer 72:201.
11. Poulakis N., A. Sarandakou, D. Rizos, L. Phocas, T. Kontozoglou and D. Polyzogopoulos. 1991. Soluble interleukin-2 receptors and other markers in primary lung cancer. Cancer 68: 1045.
12. E.C.Borden. 1992. Interferons:pleiotropic cellular modulators. Clin. Immunol. Immunopathol. 62:518.
13. Fountzilas G. and A. Zissiadis. 1993. The role of interferons in the treatment of colorectal cancer. J. Chemother. 5:271.
14. Wiesenfeld M., M.J. O'Connell, U.S. Wieand, N.J. Gonchoroff, J.H. Donohue, R.J. Fitzgibbons, J.E. Krook, J.A. Mailliard, J.B. Gerstner J.B. and R. Pazdur. 1995. Controlled clinical trials of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. J. Clin. Oncol. 13:2324.
15. Beahrs O.H., D.E. Henson, R.V.P. Hutter and B.J. Kennedy. Manual for staging of cancer/American Joint Committee Against Cancer. J.B. Lippincott Company, Philadelphia, 1992, p. 75.
16. Sueguchi T., K. Yokokawa, H. Sugao E. Nakano, T. Sonoda and A. Okuyama. 1992. Interleukin-6 activity in urine and serum in patients with bladder carcinoma. J. Urol. 148:791.
17. Vanderschueren B., J.C. Dumon, V. Oleffe, C. Heymans, J. Gerain J. and J.J. Body. 1994. Circulating concentrations of interleukin-6 in cancer patients and their pathogenic role in tumor-induced hypercalcemia. Cancer Immunol. Immunother. 39:286.
18. Watson J.M., J.L. Sensintaffar and O. Martinez-Maza. 1990. Constitutive production of IL-6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 50:6959.
19. Berek J.S., C. Chung, K. Kaldi, J.M. Watson, R.M. Knox and O. Martinez-Mara. 1991. Serum IL-6 levels correlates with disease status in patients with epitelial ovarian cancer. Am. J. Obstet. Gynecol. 194:1038.
20. Ullmann C.D., J. Schlom and J.W. Greiner. 1992. Interleukin-6 increases carcinoembryonic antigen and histocompatibility leukocyte antigen expression on the surface of colorectal carcinoma cells. J. Immunother. 12: 231.
21. Murakami S., A. Satomi, K. Ishida, H. Murai, M. Matsuki and T. Hashimoto. 1994. Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer. Cancer 74:2745.
22. Zier K., B. Gansbacher and S. Salvadori. 1996. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol. Today 17:39.